

Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)

Technology appraisal guidance

Published: 1 December 2022

www.nice.org.uk/guidance/ta848

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. Sanofi has confirmed that it does not intend to make a submission for the appraisal. This is because the technology will not be launched in the UK for treating this indication.

Information

If NHS organisations wish to consider cemiplimab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4833-8

Accreditation

